HCP Pivotal Trial Results – Adult

Results that will change how your adult patients live with their diabetes

Our clinical partners conducted the largest and most diverse clinical study of an automated insulin delivery system to date.

  • 16 world-class diabetes centers across the country
  • 440 participants (adults and children)
  • 3-month randomized controlled trial to use the iLet paired with a Dexcom G6 in everyday life

The results were published in the September 29, 2022 issue of The New England Journal of Medicine1 and Diabetes Technology & Therapeutics.2

Time in Range and HbA1c improvement in Adults using the Bionic Pancreas with Humalog and Novolog3

Values are Mean Baseline Adjusted Difference. The study was not designed to evaluate the effect of the iLet Bionic Pancreas in subgroups by baseline HbA1c. Individual user results may vary from the average values shown here. *n = iLet/Standard of Care.

By using the iLet Bionic Pancreas, your adult patients using Humalog/Novolog, on average, can have nearly 1,000 more hours Time in Range each year1

Compared to those on standard of care, Adults using the iLet Bionic Pancreas with Fiasp experienced an extra 3.1 hours of Time in Range per day 1

1 Russell, S.J., et al. (2022) A Multicenter Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. The New England Journal of Medicine 2022; 387:1161–1172. 2. Kruger, D,. et. Al. (2022) A Multicenter Randomized Trial Evaluating the Insulin-Only Configuration of the Bionic Pancreas in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics 2022; 24:697–711. 3. Data on file.

MM000056_A Rev A

Ready to GO BIONIC?

The iLet Bionic Pancreas automatically adjusts to your insulin needs so you don’t have to.